For the quarter ended December 2025, Alkermes (ALKS) reported revenue of $384.55 million, down 10.6% over the same period last year. EPS came in at $0.46, compared to $1.04 in the year-ago quarter.The reported revenue represents a surprise of +1.21% over the Zacks Consensus Estimate of $379.96 million. With the consensus EPS estimate being $0.43, the EPS surprise was +7.8%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine t ...

Management acknowledged potential generic competition for VIVITROL in 2027, noting the product's manufacturing complexity as a significant barrier to entry for competitors.The expiration of Zeppelin royalties in the second half of 2026 is expected to create a headwind for manufacturing and royalty revenue streams.VIVITROL and ARISTADA 2025 results included $27M and $14M respectively in one-time gross-to-net favorability that management explicitly stated will not recur in 2026.A non-cash inventory step-up ch ...

For 2026, Alkermes guided total revenues of $1.73 billion to $1.84 billion, including proprietary product net sales of $1.52 billion to $1.60 billion. It expects manufacturing and royalty revenues of $210 million to $240 million, reflecting scheduled expiration of certain XEPLION royalties that phase out on a country-by-country basis in the second half of 2026. The company also noted that its VUMERITY manufacturing obligations were completed in 2025, with future VUMERITY revenue expected to be solely royalt ...

Alkermes (NasdaqGS:ALKS) Q4 2025 Earnings call February 25, 2026 08:00 AM ET Company ParticipantsAmi Fadia - Managing DirectorAnya John - Research AssociateBlair Jackson - COODavid Huang - DirectorDouglas Tsao - Managing DirectorJason Gerberry - Managing DirectorJoon Lee - Managing DirectorJoseph Thome - Managing DirectorJoshua Reed - CFOJulian Pino - Biotechnology Equity ResearchRichard Pops - CEORudy Li - DirectorSandy Coombs - SVP of Investor Relations and Corporate AffairsTodd Nichols - Chief Commercial ...

Fourth Quarter and Year-End 2025 Financial Results & Business Update February 25, 2026 Forward-Looking Statements and Non-GAAP Financial Information Certain statements set forth in this presentation constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: Alkermes plc's (the "Company") expectations with respect to its current and future financial, commercial and operating performance, ...

In its upcoming report, Alkermes (ALKS) is predicted by Wall Street analysts to post quarterly earnings of $0.43 per share, reflecting a decline of 58.7% compared to the same period last year. Revenues are forecasted to be $379.96 million, representing a year-over-year decrease of 11.6%.The consensus EPS estimate for the quarter has been revised 152.2% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates dur ...

Core Insights - Alkermes plc reported strong financial results for Q3 2025, with revenues of $394.2 million, a 4% increase from $378.1 million in Q3 2024 [3][4] - The company achieved a GAAP net income of $82.8 million, with diluted earnings per share of $0.49 [3][20] - Alkermes raised its financial expectations for 2025, indicating positive momentum in its business operations [2][7] Financial Performance - Total revenues for the nine months ended September 30, 2025, were $1,091.4 million, compared to $1,127.6 million for the same period in 2024 [3] - Proprietary net sales for Q3 2025 were $317.4 million, up from $273.0 million in Q3 2024, marking a 16% increase [3][5] - Key product sales included VIVITROL at $121.1 million (up 7%), ARISTADA at $98.1 million (up 16%), and LYBALVI at $98.2 million (up 32%) compared to Q3 2024 [3][5] Profitability Metrics - GAAP net income from continuing operations was $82.8 million for Q3 2025, down from $92.8 million in Q3 2024 [3][20] - Adjusted EBITDA for Q3 2025 was $121.5 million, compared to $134.3 million in Q3 2024 [3][21] - The company reported a total operating income of $89.1 million for Q3 2025, down from $104.8 million in Q3 2024 [3][20] Research and Development - Alkermes advanced its development pipeline, particularly in the orexin 2 receptor agonist program, with positive data from the Vibrance-1 study for narcolepsy type 1 [2] - The company plans to initiate its phase 3 clinical program for alixorexton in early 2026, which is expected to be a significant growth driver [2] Updated Financial Guidance - Alkermes updated its 2025 financial expectations, raising total revenue guidance to $1,430 – $1,490 million from the previous range of $1,340 – $1,430 million [7][8] - The updated expectations for VIVITROL net sales increased to $460 – $470 million, ARISTADA net sales to $360 – $370 million, and LYBALVI net sales to $340 – $350 million [8]

Core Insights - Alkermes reported revenue of $390.66 million for the quarter ended June 2025, reflecting a year-over-year decline of 2.1% and an EPS of $0.52 compared to $0.72 a year ago, exceeding the Zacks Consensus Estimate of $338.57 million by 15.38% and delivering an EPS surprise of 26.83% [1] Revenue Breakdown - Manufacturing and Royalty revenues were $83.42 million, surpassing the average estimate of $61.5 million, but showing a year-over-year decline of 35.8% [4] - Product sales, net, reached $307.24 million, exceeding the estimated $276.98 million and representing a year-over-year increase of 14.1% [4] - Proprietary Sales for VIVITROL amounted to $121.7 million, above the estimated $111.47 million, marking an 8.8% increase year-over-year [4] - Proprietary Sales for ARISTADA were $101.3 million, exceeding the average estimate of $84.2 million, with a year-over-year growth of 17.8% [4] - Proprietary Sales for LYBALVI reached $84.3 million, compared to the estimated $79.41 million, reflecting an 18.1% year-over-year increase [4] - Manufacturing and Royalty Revenues for VUMERITY were $39.4 million, surpassing the estimated $27.92 million, with an 11.9% year-over-year increase [4] Stock Performance - Alkermes shares have returned -8.6% over the past month, contrasting with the Zacks S&P 500 composite's +3.6% change, and the stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market [3]

Financial Data and Key Metrics Changes - The company reported total revenues of $390.7 million for Q2 2025, with proprietary product net sales of $307.2 million, reflecting a 14% year-over-year growth [12][14] - GAAP net income was $87.1 million, with EBITDA of $101.6 million and adjusted EBITDA of $126.5 million for the second quarter [14] - The company ended the quarter with $1.05 billion in cash and total investments, maintaining a strong financial position [14] Business Line Data and Key Metrics Changes - VIVITROL net sales were $121.7 million, driven by growth in the alcohol dependence indication market [17] - ARISTADA net sales reached $101.3 million, with encouraging leading indicators related to underlying demand [17] - LYBALBI net sales grew 18% year-over-year to $84.3 million, with underlying TRx growth of 22% [18] Market Data and Key Metrics Changes - The proprietary product portfolio's net sales exceeded expectations, driven by strong end market demand and favorable gross to net dynamics [17] - The company anticipates Q3 net sales from the proprietary product portfolio in the range of $280 million to $300 million [12] Company Strategy and Development Direction - The company is focused on accelerating future growth through development candidates in its pipeline, particularly in the orexin portfolio [6][34] - The successful results from the Vibrance one Phase II study of elixorextin are seen as a critical step in the development of the orexin portfolio [7][10] - The company plans to advance additional orexin candidates into clinical development later this year [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving record revenues from proprietary products in 2025, anticipating performance towards the higher end of previously issued financial expectations [14][34] - The management highlighted the importance of the positive Vibrance one data as a significant stride forward for the elixorexin development program [33] Other Important Information - The company has a remaining share repurchase authorization of $200 million and may opportunistically repurchase shares depending on market conditions [14] - The company is preparing for key regulatory interactions and plans to initiate a global Phase III program in narcolepsy following the top line data from the narcolepsy type two study [22][34] Q&A Session Summary Question: Focus on visual adverse events with the Orexin program - Management acknowledged the focus on visual AEs from Wall Street and emphasized the importance of the rigorous ophthalmic exams conducted during the study [39][40] Question: Efficacy of elixorextin compared to Takeda's program - Management expressed confidence in the competitive advantage of elixorextin's dosing range and efficacy, awaiting further data from ongoing studies [48] Question: Regulatory path and potential registrational trials - Management indicated that the NT2 study data will be crucial for discussions with the FDA regarding the Phase III design [51][52] Question: Dose response and statistical analysis - Management confirmed the use of negative binomial analysis for cataplexy data and expressed confidence in the clarity of the cataplexy signal [62][63] Question: Potency selectivity of elixorextin - Management confirmed that elixorextin is 5,000-fold more selective towards the orexin 2 receptor over the orexin 1 receptor [70] Question: Safety profile extrapolation to follow-on compounds - Management noted that while similarities are expected due to the same receptor targeting, different pharmacokinetic profiles may lead to variations in safety profiles [74][75] Question: Dosing flexibility in Phase III - Management stated that dosing decisions for Phase III will be informed by the comprehensive data from the Phase II studies [82][110]

Group 1 - The article discusses the Biotech Analysis Central service, which provides in-depth analysis of pharmaceutical companies and offers a model portfolio of small and mid-cap stocks [1][2] - The service includes over 600 biotech investing articles and live chat features to assist healthcare investors in making informed decisions [2] - A promotional offer is available for new subscribers, including a two-week free trial and a discounted annual subscription price [1] Group 2 - The author previously wrote about Alkermes, focusing on potential narcolepsy data that could influence the company's future [2] - The article emphasizes that the author has no financial positions in the companies mentioned, ensuring an unbiased perspective [3]